FK506/MYCOPHENOLATE MOFETIL IN RENAL TRANSPLANTS

FK506/霉酚酸酯在肾移植中的应用

• 批准号: 6245606
• 负责人: E STEVE WOODLE
• 金额: $ 3.72万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-06 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6245606
• 关键词: FK506; clinical research; clinical trial phase I; combination chemotherapy; drug screening /evaluation; human subject; human therapy evaluation; immunosuppressive; kidney transplantation; mycophenolic acid; pharmacokinetics; transplant rejection

The objective of this study is to assess the pharmocokinetics, safety, and tolerability of FK 506 and mycophenolate mofetil when used in combination instable renal transplant recipients. 18 stable renal transplant recipients will be allowed to participate in this study. Six patients will be assigned to each treatment group (mycophenolate mofetil 500 mg BID, mycophenolate mofetil 750 mg BID and mycophenolate mofetil 1000 mg BID).

本研究的目的是评估药代动力学、安全性和 FK 506 和吗替麦考酚酯联合使用时的耐受性 不稳定的肾移植受者。 18 稳定肾移植 接受者将被允许参加这项研究。 六名患者 将被分配到每个治疗组（吗替麦考酚酯 500 mg BID，吗替麦考酚酯 750 mg BID，吗替麦考酚酯 1000 mg 出价）。